Table 1.
Patient demographics and baseline characteristics (randomized population)
| Demographic | Gliclazide (n = 18) | Vildagliptin (n = 18) |
|---|---|---|
| Age (years) | 55.4 ± 11.3 | 59.4 ± 8.9 |
| Sex (number of men) | 6 | 12 |
| BMI (kg/m2) | 30.68 ± 4.3 | 29.35 ± 4.3 |
| Duration of diabetes (years) | 4.4 ± 2.6 | 4.3 ± 2.7 |
| Duration of previous metformin treatment (months) | All patients were on metformin treatment for ≥3 months on stable dose (≥1000 mg/daily) | |
| Metformin daily dose (mg) | 1457 ± 373 | 1584 ± 528 |
| Gliclazide daily dose (mg) | 86,80 ± 28,10 | - |
Data are means ± SD unless otherwise indicated